Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Stoke Therapeutics Inc (STOK) USD0.0001

Sell:$20.95 Buy:$21.00 Change: $0.04 (0.19%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $0.04 (0.19%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $0.04 (0.19%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Stoke Therapeutics Inc is a biotechnology company that develops treatments for genetic diseases. The Company develops antisense oligonucleotide medicines that target ribo-nucleic acid (RNA) splicing to increase gene expression for the treatment of severe genetic diseases. It uses targeted augmentation of nuclear gene output (TANGO) to effect targeted enhancement of gene expression. It provides TANGO, which is a precision medicine platform for treating a category of genetic diseases, such as autosomal dominant haploinsufficiency. TANGO is designed to address protein deficiency by upregulating target protein expression.

Contact details

3 Preston Ct
United States
+1 (781) 4308200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$690.50 million
Shares in issue:
32.94 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Seth Harrison
    Independent Chairman of the Board
  • Edward Kaye
    Chief Executive Officer, Director
  • Stephen Tulipano
    Chief Financial Officer
  • Huw Nash
    Chief Operating Officer, Chief Business Officer
  • Gene Liau
    Executive Vice President, Head of Research and Preclinical Development
  • Barry Ticho
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.